Article
Mutations in the John Cunningham virus VP1 gene could predispose to the development of progressive multifocal leukoencephalopathy in multiple sclerosis patients undergoing treatment with natalizumab.
Multiple sclerosis and related disorders - 1 Nov 2021
Flores J, Anguiano O, Rivas-Alonso V, González-Conchillos H, Pérez-Saldivar M, Sotelo J, Magaña-Maldonado R, Quiñones S, Corona T, Olivares H, Hernández-González O, Martínez-Palomo A, Treviño I, Ordoñez G
Abstract excerpt
BACKGROUND: Patients with Multiple Sclerosis (MS) undergoing treatment with natalizumab (NTZ) are at risk of developing progressive multifocal leukoencephalopathy (PML) due to the reactivation of John Cunningham (JC) virus. A relevant characteristic among PML cases is the development of single nucleotide mutations in the VP1 gene of the causal JC virus. The identification of such mutations in timely manner can...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.